You just read:

Boehringer Ingelheim Launches RE-VECTO Global Program to Capture Data on Praxbind® (idarucizumab) Usage in Clinical Practice

News provided by

Boehringer Ingelheim Pharmaceuticals

15 Aug, 2016, 08:00 ET